U.S. Markets close in 4 hrs.

iCAD, Inc. (ICAD)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.97-0.02 (-0.50%)
As of 11:26AM EDT. Market open.
People also watch
IRIXICCCINODIDSYDRAD
Full screen
Previous Close3.99
Open3.98
Bid3.97 x 1000
Ask3.99 x 100
Day's Range3.97 - 4.00
52 Week Range2.82 - 6.49
Volume1,665
Avg. Volume36,471
Market Cap65.01M
Beta1.44
PE Ratio (TTM)-7.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube2 months ago

    ETFs with exposure to iCAD, Inc. : May 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iCAD, Inc. Here are 5 ETFs with the largest exposure to ICAD-US. Comparing the performance and risk of iCAD, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iCAD, Inc. :ICAD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 25, 2017
    Capital Cube2 months ago

    iCAD, Inc. :ICAD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 25, 2017

    Categories: Yahoo FinanceGet free summary analysis iCAD, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of iCAD, Inc. – Fonar Corporation, Royal Philips NV Sponsored ADR, Hologic, Inc., General Electric Company, Varian Medical Systems, Inc. and Digirad Corporation (FONR-US, PHG-US, HOLX-US, GE-US, VAR-US and DRAD-US) ... Read more (Read more...)

  • Zacks Small Cap Research2 months ago

    ICAD: Q1: Strong Detection Offsets Weakness in NMSC Revenue

    Relative to our estimates, Q1 Detection revenue was about 20% better which more than offset a 7% miss to our Therapy number – the net result was a 9% beat to our total revenue estimate.  Detection was the clear highlight with revenue up 14% yoy – but excluding MRI revenues (i.e. Strength in Detection was attributed to 3D tomo sales in Europe – management noted 7 or 8 systems were sold in Q1 – as well as from “several very large (2D) tenders.”  Management mentioned that Q1 set a new record in terms of international CAD orders.  We note that since ordering patterns can be somewhat lumpy, we have not carried that level of revenue through to our Q2 number – but we also note that management indicated interest in 3D tomo in Europe continues to solidify and, as such, we think it is reasonable to expect that product will to continue to gain traction.